双示踪剂PET/CT鉴别交叉融合肾异位患者两种原发癌及转移灶
一例交叉融合肾异位患者因双示踪剂(C-乙酸[ACT]和F-FDG[FDG])PET/CT偶然发现同时患有结肠癌和肾细胞癌(RCC)两种恶性肿瘤,各自具有特征性示踪剂亲和力。多发肝转移灶也相互排斥,RCC来源的转移灶仅ACT高摄取,结肠癌来源的转移灶仅FDG高摄取;骨和肺转移灶则难以根据原发来源区分。交叉融合肾异位是罕见畸形,RCC与第二原发恶性肿瘤共存更为罕见。
要点
- 双示踪剂PET/CT可鉴别交叉融合肾异位患者共存的两种原发癌。
- 肝转移灶示踪剂亲和力相互排斥,有助于判断原发来源。
- 骨和肺转移灶在原发来源鉴别上存在局限。
核心结论
- 双示踪剂PET/CT在本例中成功区分了结肠癌和RCC两种原发癌及其肝转移灶的各自示踪剂亲和特征。
研究设计与样本
- 单个病例报告,描述一例交叉融合肾异位患者因双示踪剂(ACT和FDG)PET/CT偶然发现两种原发恶性肿瘤及转移灶。
主要发现
- 结肠癌和RCC各自具有特征性示踪剂亲和力,肝转移灶相互排斥,RCC来源灶仅ACT高摄取,结肠癌来源灶仅FDG高摄取。
- 骨和肺转移灶无法根据示踪剂亲和力轻易区分原发来源。
临床怎么用
- 对于罕见泌尿系统畸形患者,双示踪剂PET/CT有助于鉴别多原发肿瘤及转移灶来源,但骨和肺转移灶的归因需谨慎。
局限性
- 单个病例报告,结论外推受限;骨和肺转移灶的原发来源无法通过双示踪剂PET/CT明确区分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A patient was found incidentally on dual-tracer (C-acetate [ACT] and F-FDG [FDG]) PET/CT for having crossed fused renal ectopia and 2 types of malignant tumors, colonic carcinoma and renal cell carcinoma (RCC), each having its own characteristic tracer avidity. Multiple liver metastases were also mutually exclusive, with a purely ACT-avid group of metastatic lesions from RCC and another FDG-avid group from colonic carcinoma. Bone and lung metastases, however, could not be readily distinguishable in terms of primary origins. Crossed fused renal ectopia is a rare anomaly, even rarer to have RCC coexisting with a second primary malignancy.
引用
- Ho CL, Chen S, Leung YL, et al. Dual-Tracer PET/CT Differentiates 2 Types of Primary Cancers and Metastases in a Patient With Crossed Fused Renal Ectopia. Clin Nucl Med. 2019. PMID: 30608912. doi:10.1097/RLU.0000000000002390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。